Belite Bio, Inc. (NASDAQ: BLTE) saw its stock soar 5.16% in Monday's intraday trading following the release of its third-quarter 2025 financial results and a corporate update that highlighted significant progress in its drug development pipeline.

The clinical-stage biopharmaceutical company, focused on developing novel therapeutics for degenerative retinal diseases, reported several key achievements that have bolstered investor confidence. Notably, Belite Bio announced the completion of enrollment in its pivotal phase 3 PHOENIX trial for geographic atrophy, a significant milestone in advancing its lead candidate, Tinlarebant. Additionally, the company completed its pivotal phase 3 DRAGON trial in Stargardt disease, with final topline data expected in the fourth quarter of 2025.

Investors were particularly encouraged by regulatory developments, as China's National Medical Products Administration (NMPA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) have agreed to accept New Drug Applications for Tinlarebant in the treatment of Stargardt disease. This acceptance, based on interim analysis results, signals potential accelerated pathways to market approval in these regions. Furthermore, Belite Bio's strong financial position, with $275.6 million in cash and equivalents as of September 30, 2025, was bolstered by the completion of a $15 million registered direct offering and a $125 million private placement. This robust cash runway is expected to support the company's ongoing clinical trials and potential commercialization efforts.